Clinical Trial Update: Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial in resectable stage IIA-IIIB non-small cell lung cancer evaluating Sintilimab (PD-1 inhibitor) plus Anlotinib and chemotherapy; curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Chemotherapy (chemotherapy)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Sintilimab, Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING